EPElena A. Polyanskaya

Elena A. Polyanskaya

*This is an algorithmically generated author record based on publicly available information.

Elena A. Polyanskaya has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of atrial fibrillation paroxysm during ST-segment elevation myocardial infarction on the prognosis of patients under long-term follow-up

    by E. N. Safarov, V. S. Koryagin, N. A. Koziolova, E. A. Polyanskaya

    Objective. To evaluate the impact of paroxysmal atrial fibrillation (AF) during the development of ST segment elevation myocardial infarction (MI) on the prognosis of patients during long-term follow-up. Materials and methods. The study presents the results of the second stage (outpatient) of a prospective, two-stage, open-label, observational clinical trial. To assess the contribution of AF to the unfavorable prognosis of patients with ST-segment elevation MI, patients were divided into two groups. The first group included 42 patients (36.8 %) with ST-segment elevation MI without AF during hospitalization and in their medical history; the second group included 72 patients (63.2 %) with ST-segment elevation MI and paroxysmal AF during the index hospitalization for MI. To register an unfavorable prognosis, primary endpoints were determined - cardiovascular death associated with the development of recurrent MI, acute decompensation of chronic heart failure (ADHF), acute cerebrovascular accident (ischemic, hemorrhagic strokes, intracerebral hemorrhage, acute brain circulation disorders), as well as secondary endpoints: fatal recurrent MI, ADHF, stroke. Results. The follow-up duration was 22.2 ± 4.5 months from the first day of the index hospitalization with ST-segment elevation MI. During the follow-up, permanent AF was registered in 12 (16.7 %) patients of the second group, persistent/paroxysmal AF was registered in 35 (48.6 %), and recurrent paroxysms were not registered in 25 (49.0 %) of 51 patients with newly diagnosed AF during ST-segment elevation MI. In the first group, AF was newly diagnosed in 4 (9.5 %) patients during the follow-up. During 2 years of follow-up, the incidence of the primary endpoint was statistically significantly higher in the group of patients with AF (p = 0.004), as were the number of patients with a fatal outcome (p = 0.004) and the incidence of fatal stroke (p = 0.020). In case of paroxysmal AF development in patients with ST-segment elevation MI during index hospitalization, the OR of fatal events during 2 years of observation increases by 3.877 times (95 % CI 1.508–10.195), RR – by 2.399 (95 % CI 1.285–4.941), the OR of the frequency of fatal events increases by 4.021 times (95 % CI 1.518–10.946), RR – by 2.553 times (95 % CI 1.305–5.569), the OR of cardiovascular death – by 4.334 times (95 % CI 1.095–19.951), RR – by 3.501 (95 % CI 1.077–14.636), the OR of fatal stroke – by 1.388 (95 %CI 1.367–1.442), RR – 1.328 (95 %CI 1.265–1.396). Univariate analysis showed that the development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increased the Odds ratio of CV death developing during 2 years of follow-up by 3.637 times (95 % CI 1.071–12.351, p = 0.038). The incidence of fatal recurrent MI and ADHF did not differ between the groups. Conclusions. During a two-year follow-up, 48.6 % of patients who had a STEMI and an episode of AF died from cardiovascular causes, which is 2.5 times higher than among those without rhythm disturbances (19.0 %) (p = 0.004). The development of paroxysmal AF during the index hospitalization with ST-segment elevation MI increases the odds ratio for the development of cardiovascular death over 2 years of follow-up by 3.637 times. The main cause of death in patients who had a STEMI with an episode of AF was stroke, the OR of which increased by 1.388 times, and the RR of which increased by 1.328 times. The incidence and timing of fatal recurrent MI and ADHF were not associated with paroxysmal AF in patients with ST-segment elevation MI.

  • Open Access

    Predictors of atrial fibrillation in patients with ST-segment elevation myocardial infarction

    by E. N. Safarov, N. A. Koziolova, E. A. Polyanskaya, V. S. Koryagin

    Objective. To determine the predictors of atrial fibrillation (AF) development in patients with ST-segment elevation myocardial infarction (STEMI). Materials and methods. The study presents the results of the first (in-hospital) stage of a prospective, two-stage, open-label, observational clinical trial with a retrospective assessment of the patient data prior to their enrollment in the study. Over a 2-year period, 167 patients with STEMI were sequentially included into the study on admission to a multidisciplinary hospital according to the inclusion and exclusion criteria. To determine the predictors of AF development in STEMI patients, they were divided into 2 groups: Group 1 comprised 140 patients (83.8 %) with STEMI and no AF during hospitalization or in their medical history; Group 2 included 27 patients (16.2 %) with STEMI who experienced an AF paroxysm during hospitalization. Results. The prevalence of AF among 167 hospitalized patients with STEMI was 16.2 % (n=27). In 9.6 % of cases, AF paroxysm was verified for the first time, while in 6.8 % it was a manifestation of a pre-existing paroxysmal form. Systolic blood pressure BP 90 mmHg, heart rate 50 bpm and 110 bpm, and Killip class 1 increased the relative risk (RR) of AF paroxysm in MI patients by 2.3-fold, 6.1-fold, and 3.0-fold, respectively. Comorbid conditions such as obesity, chronic heart failure, and a history of pulmonary pathology increased the RR of AF by 2.6-fold, 2.3-fold, and 2.2-fold, respectively. Pre-admission use of renin-angiotensin-aldosterone system (RAAS) blockers and beta-blockers reduced the RR of AF development by 71 %, whereas the need for insulin therapy increased by 3.1-fold. In addition to the well-known predictors of AF development in MI associated with cardiac and renal remodeling, new ones were identified: left atrial contractile dysfunction index 40 %; left ventricular ejection fraction (LVEF)-to-indexed left atrial volume ratio 1.1; cystatin-based glomerular filtration rate 45 ml/min/1.73 m2; urinary albumin-to-creatinine ratio 300 mg/g; and creatinine-to-LVEF ratio. These increased the RR by 7.1-fold, 6.7-fold, 2.7-fold, 3.1-fold, and 2.7-fold, respectively. Among the new biomarkers associated with AF development in MI, the following were identified: blood apolipoprotein B100 (ApoB100) concentration 100 mg/dL; monocytes-to-high-density lipoprotein cholesterol ratio 26.5; tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) 124.2 ng/ml; platelet-to-lymphocyte ratio 212.1; inflammatory burden index 36.85; the combination of the GG genotype of the ApoB gene polymorphism Arg3500Gln (rs5742904) with the ID genotype of the fibrinogen alpha (FGA) gene polymorphism rs35496957. These increased the RR by 3.5-fold, 2.8-fold, 5.6-fold, 2.5-fold, 3.3-fold, and 3.6-fold, respectively. Conclusions. The study confirmed the clinical and historical predictors of AF paroxysm development in patients with STEMI and identified novel predictors associated with coupled structural and functional remodeling of the left and right ventricles, in combination with renal dysfunction, lipid metabolism disorders involving the apolipoprotein system, tissue fibrosis due to increased TIMP-1 levels, activation of nonspecific inflammation, anemia and pathological polymorphism of the ApoB100 and FGA genes.

  • Open Access

    Predictors of the formation of long-term post-COVID syndrome with the main symptom of dyspnea in patients with a severe course of a new coronavirus infection

    by Olga V. Masalkina, Anna I. Chernyavina, Natalia A. Koziolova, Elena A. Polyanskaya

    Objective: to determine the predictors of the formation of long-term post-COVID syndrome with the main symptom of dyspnea in patients with severe new coronavirus infection (NCVI). Materials and methods: A single-stage screening clinical study with a retrospective assessment of the course of NCVI was carried out. Over the course of 4 years, 878 patients went to the clinic for shortness of breath 3 or more months after suffering from NKVI. Long-term post-COVID syndrome was verified in 205 (23.35 %) patients with the main symptom of dyspnea without distinction by sex, who were included in the study according to the inclusion and non-inclusion criteria. Hospitalization during NCVI was defined as a severe course of infection. Depending on the presence or absence of hospitalization during NCVI, patients with dyspnea and long-term post-COVID syndrome included in the study were divided into two groups. The first group included 103 patients with dyspnea and prolonged post-COVID syndrome and severe NCVI, the second group included 102 patients with mild NCVI and did not require hospitalization. Results: The mean age of the patients was (57.15 ± 12.4) years. Clinical and anamnestic analysis showed that regardless of the severity of the NCVI suffered, the group of patients with dyspnea after the onset of NCVI after 7.3 [3.2; 12.8] months were comparable in terms of sex, age, cardiovascular risk factors, concomitant pathology, structure, frequency and doses of constantly used drugs, indicators reflecting the state of the heart, filtration function of the kidneys, ferrokinetics, markers of nonspecific inflammation. The severity of dyspnea according to the mMRC 2 questionnaire in patients with a history of severe NCVI is associated with an increase in the odds ratio (OR) the formation of long-term post-COVID syndrome by 3.704 times, relative risk (RR) by 1.630 times; with a decrease in SaO2 ≤ 96 % after a 6-minute walking test, the OR increased by 5.828 times, the RR by 1.891 times; with lung damage of more than 45 % during the acute period of NCVI, the OR increased 2.772-fold, the RR – 1.981-fold; when anxiety and depression occurred more than 6 points on the HADS scale, the OR increased by 12.142 times, the RR – by 2.839 times; with the development of cognitive impairment on the MMSE scale ≤ 27 points, the OR increased 6.117-fold, the RR – 4.528-fold; when the N-terminal fragment of the brain natriuretic propeptide (NT-proBNP) increased by more than 139 pg/ml, the OR increased by 5.553 times, and the RR increased by 3.962 times; at a blood concentration of caspase 6 of more than 28.8 pg/ml, the OR increased 4.861-fold, and the RR increased 3.962-fold. Conclusion: The course of long-term post-COVID syndrome in patients who have had severe forms of NCVI is characterized by more pronounced shortness of breath, the presence of multiple symptoms that worsen the quality of life, and a statistically more significant decrease in tolerance to physical activity. The presence and severity of anxiety, depression, cognitive impairment, increased levels of myocardial stress assessed by NT-proBNP and panoptosis assessed by caspase level 6 in the normal range are predictors of the development of long-term post-COVID syndrome in patients with dyspnea who have experienced severe NCVI in the acute period.

  • Open Access

    Predictors of the Development of Newly Diagnosed Chronic Heart Failure in Patients with Shortness of Breath in Long-Term Post-COVID Syndrome

    by O. V. Masalkina, A. I. Chernyavina, N. A. Koziolova, E. A. Polyanskaya, S. V. Mironova, E. V. Ulybina

    Aim To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome. Material and methods This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified. At the second stage, a group of 192 patients with two or more diagnostic criteria for CHF who met the inclusion criteria and had no exclusion criteria was selected. The patients selected for the second stage were divided into two groups based on the blood concentration of the N-terminal pro-brain natriuretic peptide (NT-proBNP): the first group included 108 patients with a NT-proBNP value of ≤125 pg/ml, and the second group of 84 patients with a NT-proBNP value of >125 pg/ml. Results Newly diagnosed CHF was found in 84 (9.57%) patients with dyspnea, who sought medical care for long-term post-COVID syndrome with three or more diagnostic criteria (symptoms/signs, structural and functional changes in the heart according to echocardiography, increased NT-proBNP concentration), mainly with preserved left ventricular ejection fraction (LVEF) (97.9%). With an increase in the left ventricular myocardial mass index (LVMI) >110 g/m 2 , the odds ratio (OR) of developing newly diagnosed CHF increased by 2.201 times and the relative risk (RR) increased by 1.801 times; with the development of pneumonia associated with COVID-19, the OR increased by 45.5% and the RR by 70.8%; with the development of pneumonia requiring hospitalization in patients with COVID-19, the OR increased by 34.7% and RR by 54.7%; with an increase in the erythrocyte sedimentation rate >11 mm/h, the OR increased by 41.7% and the RR by 74.1%; with a decrease in the blood concentration of potassium 178 μg/ml in combination with an iron transferrin saturation ratio 28.2 pg/ml, the OR increased by 28.8% and the RR by 35.4%. Conclusion Among 878 outpatients who sought treatment at the polyclinic for shortness of breath in long-term post-COVID syndrome, the prevalence of newly diagnosed CHF verified by three or more diagnostic criteria was 9.57%, mainly with preserved LVEF. The development of CHF in these patients was related with more severe forms of previous COVID-19 complicated by pneumonia and requiring hospitalization, an increase in LVMI to > 110 g/m 2 , activation of low-grade nonspecific inflammation, metabolic disorders due to a decrease in potassium even within the normal range, latent iron deficiency, and an increase in the PANoptosis processes.


  • Open Access

    Features of the State of the Collagenolysis System and risk factors of Its Changes in Patients with Long-Term Post-COVID Syndrome

    by O. V. Masalkina, E. A. Polyanskaya, N. A. Koziolova, A. I. Chernyavina

    Objective: to assess the state of the collagenolysis system in patients with long-term post-COVID syndrome, to determine the features and risk factors of its changes. Materials and methods. The study included 178 patients who had had a new coronavirus infection (NCVI) 12 weeks or more ago, depending on the presence or absence of symptoms of long-term post-COVID syndrome, patients who had NCVI 12 or more weeks ago were divided into 2 groups: the first group consisted of 88 patients with Long-covid symptoms; the second group consisted of 90 subjects without any symptoms of Long-covid. Results. The median period after NCVI was 8.5 [3.6; 12.4] months. In all patients who underwent NCVI, tissue inhibitor of matrix metalloproteinase type 1 (TIMP1) was higher than the reference value (135 pg/ml). In the patients of the first group, TIMP1 was lower than in the second group: 315.5 [145.0; 620.0] pg/mL vs. 513.5 [220.0; 865.0] pg/mL (p < 0.001). Therefore, in long-term post-COVID syndrome, a collagenolytic pattern develops against the background of an increased risk of fibrosis. Conclusion. In patients who have undergone NCVI with a long-term post-COVID syndrome, the state of the collagenolysis system is characterized by the development of a collagenolytic pattern against the background of the prevailing processes of collagen formation in comparison with asymptomatic patients who had NCVI 12 weeks ago or more, which can be considered as a pathogenetic mechanism for the formation of “Long Covid”.

  • Open Access

    Real-world data on managing patients with coronary artery disease and multifocal atherosclerosis. Results of the 12-month international clinical registry of patients with identified multifocal atherosclerosis in the Russian Federation and Eurasian countries (KAMMA)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, А. Ю. Васькин, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study real-world data on managing patients with coronary artery disease (CAD) and multifocal atherosclerosis (MFA) for 12 months by outpatient cardiologists.Material and methods. KAMMA is a real-world registry organized by the Eurasian Association of Therapists. The main branch included men and women over 18 years of age with confirmed atherosclerosis in two or more arterial systems and one or more risk factors for atherosclerosis. The start date for patient recruitment was February 1, 2022 and the end date was November 27, 2022. The design included 3 following visits: 1 — baseline, 2 — after 6 months, 3 — after 12 months. Twentyeight research centers were located in 7 federal districts of the Russian Federation, as well as in the Republics of Kazakhstan, Uzbekistan and Belarus.Results. A patient population (n=2905) was formed, all of whom had verified CAD. The mean age was 66,0 [59,0; 72,0] years (men — 60,3%). Low-density lipoprotein cholesterol decreased by 20,4% over 12 months, while non-high-density lipoprotein cholesterol — by 12,7%. Over 12 months, lipid-lowering therapy did not undergo significant changes. Statin monotherapy was maintained in 83%, of which only 53,7% of patients received high-dose therapy. Combined statin+ezetimibe therapy was used in 12,4%, while statin+ezetimibe+PCSK9 inhibitor — in 4,6%. During the 1-year follow-up, antithrombotic therapy was not enhanced. Low prescription rate of combination therapy with antiplatelet agents (15,7%) and low-dose rivaroxaban and acetylsalicylic acid (7,9%) remained. By the follow-up end, a high incidence of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.Conclusion. Despite the fact that patients with MFA have a very high cardiovascular risk, routine management of these patients is characterized by high clinical inertia. During the 1-year follow-up, lipid-lowering and antithrombotic therapy was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved and a high rate of major adverse cardiovascular events was observed in patients included in the registry.


  • Factors influencing caspase-6 levels in patients with dyspnea associated with long COVID

    by Olga V. Masalkina, Anna I. Chernyavina, Natalya A. Koziolova, Elena A. Polyanskaya

    BACKGROUND: Apoptosis is a genetically programmed form of cell death. It is essential for maintaining homeostasis in the body. A key feature of apoptosis is the maintenance of normal cell population, with caspases playing a central role and potentially contributing to the pathogenesis of specific long COVID phenotypes. Identifying the role of caspases and their association with clinical markers may provide additional evidence for the causes of this syndrome. AIM: To determine the role of caspase-6 in patients with dyspnea or its equivalents in long COVID. METHODS: A single-center, cross-sectional observational study was conducted over a 3-year period, when 878 patients sought medical care for dyspnea or its equivalents at an outpatient clinic, with 186 patients included in the study. RESULTS: All patients in the study had caspase-6 levels within the reference range. Caspase-6 concentration in the long COVID group (group 1, n = 86) was significantly lower than that in the control group (group 2, n = 100) with no history of COVID-19. To identify risk factors for decreased apoptotic activity and increased pro-inflammatory responses, 86 patients with long COVID and dyspnea were stratified into two subgroups based on caspase-6 levels: 33 patients (38.4%) with caspase-6 26.5 pg/ml and 53 patients (61.6%) with caspase-6 ≤ 26.5 pg/ml. Severe COVID-19 pneumonia was associated with a nearly 7-fold increase in the relative risk (RR) of reduced apoptotic activity and an increase in pro-inflammatory responses in the post-COVID period: RR 6.85; 95% confidence interval (CI) 1.02–143.74. It also increased the risk of elevated N-terminal pro-B-type natriuretic peptide level 120 pg/ml by more than 2-fold (RR 2.41; 95% CI 1.27–5.14), carotid-femoral pulse wave velocity 10.6 m/s by 4-fold (RR 4.10; 95% CI 1.45–11.77), aortic pulse wave velocity 8.3 m/s by 3-fold (RR 3.22; 95% CI 1.31–9.62), increased ferritin level 152.5 ng/ml. It reduced transferrin saturation 19.8% by 2.5-fold (RR 2.49; 95% CI 1.23–5.75), and increased tissue inhibitor of metalloproteinases-1 level 376.1 ng/ml by 69% (RR 1.69; 95% CI 1.10–2.72). CONCLUSION: Long COVID-related dyspnea is associated with reduced caspase-6 levels, which correlate with impaired apoptotic activity and heightened inflammatory responses. Proposed pathophysiological mechanisms underlying caspase-6 deficiency include activation of myocardial stress pathways, increased collagen deposition, hyperferritinemia, and arterial stiffness.

  • Open Access

    Patients With Non-Obstructive Coronary Artery Disease and Polyvascular Disease. Sub-Analysis of the Real-World Registry KAMMA (Clinical Registry on Patient Population With Polyvascular Disease in the Russian Federation and Eurasian Countries)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, A. Yu. Vaskin, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study the clinical status and data of laboratory and instrumental examination of patients with non-obstructive ischemic heart disease (IHD) and multifocal atherosclerosis (MFA) included in the KAMMA registry. Material and methods. The subanalysis included 1,893 IHD patients who underwent coronary angiography (CAG) and ultrasonic examination of peripheral arteries. Based on the CAG data, patients were divided into two groups: group 1, patients with obstructive coronary atherosclerosis (CA) (maximum stenosis ≥50% and/or history of percutaneous coronary intervention/coronary artery bypass grafting, n=1728; 91.3%) and group 2, patients with non-obstructive CA (maximum stenosis Results. A comparative analysis based on the degree of coronary obstruction in patients with verified IHD who were included in the KAMMA registry showed that 8.7% of them had coronary artery stenosis of less than 50%. The overwhelming majority of patients with non-obstructive CA had MFA affecting the brachiocephalic arteries in 94.3% and the lower extremity arteries in 40.2%. Among patients with non-obstructive IHD, women predominated; risk factors such as smoking and type 2 diabetes mellitus were less frequent in this group than in the obstructive IHD group. Patients with non-obstructive CA more frequently had a history of dyslipidemia; they had higher total cholesterol and non-high-density lipoprotein cholesterol; and they more frequently received moderate-intensity statin therapy than patients with obstructive CA (55.8% vs. 34.5%). Characteristic features of patients with non-obstructive CA were less severe IHD and less frequent history of acute coronary syndrome. However, the incidence of stroke, peripheral arterial thrombosis, and chronic arterial insufficiency of the lower extremities did not differ in groups 1 and 2, whereas the incidence of paroxysmal atrial fibrillation was higher in the non-obstructive IHD group. Conclusion. IHD patients without coronary obstruction also require assessment of the peripheral arterial status, as they may have advanced MFA, which should be taken into account when choosing the “aggressiveness” of therapy.


  • Open Access

    Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, А. Ю. Васькин, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To investigate the prevalence and characteristics of polyvascular disease in the Eurasian region's population with one or more previously established locations of atherosclerotic arterial damage, and to evaluate the diagnostic importance of the ankle-brachial index (ABI) as a marker for polyvascular disease (PVD).Material and methods. A total of 1837 patients were included in the main branch of the KAMMA registry (patients with PVD), among which 91,6% had coronary artery disease (CAD) (n=1683). For further analysis, the group of patients with CAD was combined with 1222 patients included in the second branch of the registry — KAMMA-cardio, forming a patient population (n=2905), in which all patients had verified CAD. The mean age of patients was 66,0 [59,0; 72,0] years, with 60,3% being male. Peripheral arteries was assessed using ultrasound examination.Results. PVD was present in 95,6% of patients with coronary atherosclerosis: dual-region involvement was observed in 51,3% of patients, three-region involvement in 37,1%, four-region involvement in 3,4%, and five-region involvement in 2,0%. Stenoses of the common carotid artery were observed in 71% of patients, internal carotid artery — in 68%, lower limb artery — in 52%, and renal and mesenteric artery — in 8,3%. There were following diagnostic effectiveness of the ABI for detecting patients with lower limb artery stenosis was: sensitivity — 58,0%, specificity — 83,6%. The quality of antithrombotic and lipid-lowering therapy was insufficient.Conclusion. In the overwhelming majority (95,6%) of patients with CAD in the KAMMA registry, PVD was revealed, with nearly half of the patients having involvement in three or more arterial zones. In the patient population with CAD, there should be an active effort to identify patients with PVD, using at least the ABI determination and active modern antithrombotic and lipid-lowering therapy according to current clinical guidelines.


  • Open Access

    Predictors of the Development of Associated Clinical Conditions in Working-Age Patients With Cardiovascular Risk Factors in Conditions of High Adherence to Treatment

    by N. A. Koziolova, A. I. Chernyavina, E. A. Polyanskaya

    Aim . To determine predictors for the development of associated clinical conditions (ACC) in patients of working age with cardiovascular risk factors (CVRFs) in the conditions of high compliance with the treatment and healthy lifestyle (HLS). Material and methods . The study included 364 patients with CVRFs without target organ damage and a history of ACC. Mean age was 42.24±8.08 years. Patients were examined in consistency with the Russian Society of Cardiology (RSC) 2020 guidelines for arterial hypertension and chronic heart failure. The follow-up period was 6.45±0.42 years. 350 patients completed the study, 9 patients died during the follow-up period, and 5 were lost to follow-up. Patients were divided into two groups based on the development of ACC. The first group consisted of 56 (16%) patients with verified ACC, the second group included 294 (84%) patients without ACC. Results . Regression logistic and correlation analyses confirmed the prognostic significance for the development of ACC by 12 indicators. The risk of ACC in smokers was increased more than 7 times (odds ratio (OR) 7.44, 95% confidence interval (CI): 3.42-16.21), and when type 2 diabetes mellitus (DM) developed, more than 9 times (OR 9.47, 95% CI: 4.36-20.59); with chronic kidney disease (CKD), more than 6 times (OR 6.75, 95% CI: 3.41-13, 37); with a history of COVID-19 (COronaVIrus Disease 2019) pneumonia, 7 times (OR 7.11, 95% CI: 3.04-16.58); with left ventricular hypertrophy (LVH), 6 times (OR 6, 35, 95% CI: 3.14-12.83); with CAVI index>7.2, almost 3 times (OR 2.69, 95% CI: 1.48-4.86); with PVWcf (carotid-femoral pulse wave velocity) >13 m/s, more than 5 times (OR 5.61, 95% CI: 2.79-11.28); with R-AI index (augmentation index) >1, more than 2 times (OR 2.26, 95% CI: 1.3-3.9); and with an increase in the indexed left atrial volume (ILAV) >27 ml/m2, more than 8 times (OR 8.80, 95% CI: 4.61-16.79). In the presence of polymorphisms in the form of homozygosity for the minor allele of the AGT gene (Thr174Met, rs4762), the risk of developing ACC increased 14 times (OR 14.13, 95% CI: 4.69-42.57), the APOE gene (Cys130Arg, rs429358), 11 times (OR 11.18, 95% CI: 4.18-29.93), and in the intron of the PRARα gene (rs4253778), 8 times (OR 8.11, 95% CI: 3.75-17.53). Conclusion . The development of ACC in patients with high compliance with treatment and a healthy lifestyle is associated with smoking, type 2 diabetes and CKD, a history of COVID-19 pneumonia, LVH, increased ILAV >27 g/m2, more pronounced arterial stiffness assessed by an increase in CAVI indices >7.2, R-AI >1, and PWVcf >13 m/s; and with the presence of polymorphism of the AGT, APOE and PPARα genes in the form of homozygosity for the minor allele.